MoonLake Immunotherapeutics
MLTX
46 hedge funds and large institutions have $116M invested in MoonLake Immunotherapeutics in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
10% more funds holding
Funds holding: 42 → 46 (+4)
6% more capital invested
Capital invested by funds: $109M → $116M (+$6.86M)
4.41% more ownership
Funds ownership: 89.42% → 93.83% (+4.4%)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$2.03M |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$711K |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$576K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$508K |
| 5 |
Millennium Management
New York
|
+$363K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.52M |
| 2 |
HM
HealthCor Management
New York
|
-$613K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$365K |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$361K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$106K |
MLTX Hedge Fund Activity: Q2 2021 in Review
46 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2021, worth a combined $116M — up 6.3% from $109M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MLTX positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 9 trimmed.
The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $2.03M. The largest seller was Logos Global Management, cutting an estimated $1.52M.
- 46 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2021, up from 42 in Q1 2021.
- Funds reported $116M of MoonLake Immunotherapeutics stock for Q2 2021, up 6.3% quarter-over-quarter.
- 6 funds opened new MoonLake Immunotherapeutics positions in Q2 2021 and 2 closed out, a net change of +4 holders.
- The largest MoonLake Immunotherapeutics buyer in Q2 2021 was STALEY CAPITAL ADVISERS, an estimated $2.03M added.
- The largest MoonLake Immunotherapeutics seller in Q2 2021 was Logos Global Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q2 2021.